Vor Bio is the latest cell therapy company to reach the end of the road. | Vor Bio is the latest cell therapy company to ...

GSK has shared the data behind its phase 3 liver disease win, revealing patients on linerixibat reported reductions in ...

Korro Bio is laying off a fifth of its workforce as the Novo Nordisk-partnered biotech funnels resources to its ...

The FDA has appointed its first chief artificial intelligence officer, with an eye on supporting the agency’s internal IT ...

RallyBio is steering around more tight corners as it announces a further 40% reduction in staffers just weeks after ...

The Food and Drug Administration is going all in on artificial intelligence. | The Food and Drug Administration is going all ...

NKGen Biotech CEO Paul Song, M.D., is putting his money where his mouth is, investing $2.65 million of his own cash to help ...

Takeda has shot down candidates acquired in its $525 million Maverick Therapeutics takeover, blowing a hole in its oncology R ...

California investment firm Vivo Capital has secured $740 million in commitments to be aimed at preclinical- and ...

Mersana Therapeutics only has eyes for Emi-Le. Seeking to extend its cash runway into mid-2026, the biotech is laying off 55% ...

C4 Therapeutics is sawing off another part of its solely owned pipeline, this time ending work on its clinical-stage BRAF ...

Beacon Therapeutics may have found a guiding light in a disease area where other companies have stumbled with its ...